A High-Throughput Assay for Probes of the Flavivirus RNA Guanylyltransferase

黄病毒 RNA 鸟苷基转移酶探针的高通量测定

基本信息

批准号：
8204514
负责人：
Brian Geiss
金额：
$ 3.68万
依托单位：
COLORADO STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-12-06 至 2012-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8204514
关键词：
Active Sites Amino Acids Antiviral Agents Binding Binding Proteins Binding Sites Biochemical Biological Biological Assay Categories Cell Culture Techniques Cells Characteristics Chemicals Code Computer Simulation Culicidae Dengue Dengue Virus Development Disease Drug Delivery Systems Enzymes Evaluation Flavivirus Flavivirus Infections Foundations GTP Binding Genomics Goals Growth Guanosine Guanosine Monophosphate Guanosine Triphosphate Human In Vitro Infection Laboratories Lead Life Medical Methyltransferase Modeling Monitor Morbidity - disease rate Mutation N-terminal National Institute of Allergy and Infectious Disease Patients Pharmaceutical Preparations Positioning Attribute Property Proteins Publishing RNA RNA Caps Replicon Resolution Screening procedure Site Solid Structure Structure-Activity Relationship Testing Therapeutic Translations Validation Viral Viral Genome Virus West Nile virus Yellow Fever Yellow fever virus analog base chemotherapeutic agent cost effective cytotoxic cytotoxicity design drug development guanylyltransferase high throughput screening human morbidity human mortality in vitro activity in vivo inhibitor/antagonist interest mRNA guanylyltransferase mortality novel pathogen pre-clinical public health relevance scaffold small molecule socioeconomics therapy development viral RNA

项目摘要

DESCRIPTION (provided by applicant): Infection by flaviviruses such as dengue, yellow fever, and West Nile is a major medical and socio-economic problem worldwide, yet effective antiviral therapeutics to treat flavivirus infection are not currently available. As such, it is imperative that potent, selective, and cost-effective antiviral compounds be identified. The overall goal of this project is the discovery of novel inhibitors of the guanylyltransferase (GTase) active site of the flavivirus RNA capping enzyme (CE) that could serve as effective broad-spectrum chemotherapeutic agents for the treatment of flavivirus infection. The CE generates the cap structure at the 5' end of viral RNAs that is required for efficient translation of the viral genome and is essential for viral growth. The GTase transfers a guanosine monophosphate from GTP to the 5' end of the genomic RNA to produce the cap 0 structure. Disruption of GTP binding by the CE inhibits viral replication, indicating that this function is critical to viral viability. We recently published that the GTP binding site harbors the GTase active site, increasing interest in the GTP-binding site as a potential drug target site. We have designed and successfully implemented a simple and rapid in vitro high-throughput assay to identify compounds that interfere with GTP binding by the CE. In this application we propose to expand on our previous screening by performing additional HTS within the MLPCN with the goal of identifying and optimizing a chemically diverse set of CE GTP-binding inhibitors in order to identify lead compounds for drug development. The best inhibitors (in terms of breadth, potency and drug-like characteristics) will be tested for their ability to inhibit GTase enzymatic activity, cytotoxicity, and antiviral activity in cell culture. This project will result in the rapid and efficient identification of inhibitors of flavivirus replication with the ultimate goal of describing lead compounds with drug-like properties suitable for preclinical development for the treatment flavivirus infection. PUBLIC HEALTH RELEVANCE: Disease resulting from mosquito-borne flavivirus infection causes significant human morbidity and mortality throughout the world, yet there currently are no effective therapeutics to treat infected patients. The goal of this project is to identify and characterize broadly active antiviral compounds targeting the guanylyltransferase active site of the conserved flavivirus capping enzyme.

描述（由申请人提供）：黄病毒（例如登革热、黄热病和西尼罗河病毒）感染是世界范围内的一个主要医学和社会经济问题，但目前尚无治疗黄病毒感染的有效抗病毒疗法。因此，必须鉴定出有效、选择性和具有成本效益的抗病毒化合物。该项目的总体目标是发现黄病毒RNA加帽酶（CE）鸟苷酸转移酶（GTase）活性位点的新型抑制剂，可作为治疗黄病毒感染的有效广谱化疗药物。 CE 在病毒 RNA 的 5' 端生成帽子结构，这是病毒基因组有效翻译所必需的，并且对于病毒生长至关重要。 GTase 将单磷酸鸟苷从 GTP 转移到基因组 RNA 的 5' 端，以产生 cap 0 结构。 CE 破坏 GTP 结合会抑制病毒复制，表明该功能对于病毒活力至关重要。我们最近发表了 GTP 结合位点含有 GTase 活性位点的文章，这增加了人们对 GTP 结合位点作为潜在药物靶位点的兴趣。我们设计并成功实施了一种简单快速的体外高通量测定法，以鉴定干扰 CE 结合 GTP 的化合物。在此应用中，我们建议通过在 MLPCN 内执行额外的 HTS 来扩展我们之前的筛选，目的是识别和优化一组化学上多样化的 CE GTP 结合抑制剂，从而识别用于药物开发的先导化合物。最好的抑制剂（在广度、效力和药物样特征方面）将在细胞培养物中测试其抑制 GTase 酶活性、细胞毒性和抗病毒活性的能力。该项目将快速有效地鉴定黄病毒复制抑制剂，最终目标是描述具有药物样特性的先导化合物，适合用于治疗黄病毒感染的临床前开发。公共卫生相关性：由蚊媒黄病毒感染引起的疾病导致全世界人类显着发病和死亡，但目前尚无有效的治疗方法来治疗感染患者。该项目的目标是鉴定和表征针对保守黄病毒加帽酶的鸟苷基转移酶活性位点的具有广泛活性的抗病毒化合物。